Related Experiment Video
Updated: Apr 28, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
20.3K
Factors associated with treatment interruption for Hepatitis C.
Luciana Oliveira de Rezende Melo1, Denise Leite Maia Monteiro1, Nádia Cristina Pinheiro Rodrigues2
1Assistant Professor, Universidade Estácio de Sá, Rio de Janeiro, RJ, Brazil.
Revista Da Associacao Medica Brasileira (1992)
|June 12, 2014
Summary
Advanced liver fibrosis and specific Hepatitis C virus (HCV) genotypes significantly increase the risk of treatment interruption. Identifying these factors aids in optimizing HCV therapy adherence.
Area of Science:
- Hepatology
- Infectious Diseases
- Clinical Research
Background:
- Hepatitis C virus (HCV) infection is a significant global health concern.
- Treatment interruption in Hepatitis C can lead to suboptimal outcomes and disease progression.
- Identifying predictors of treatment cessation is crucial for improving patient management.
Purpose of the Study:
- To identify key risk factors associated with the interruption of Hepatitis C treatment.
- To analyze the influence of demographic, clinical, and virological factors on therapy adherence.
Main Methods:
- Retrospective cohort study of patients treated for Hepatitis C between 2001 and 2009.
- Investigation of factors including liver fibrosis, HCV genotype, age, gender, comorbidities, and treatment details.
- Statistical analysis using survival curves and Cox regression models.
Main Results:
- Patients with advanced liver fibrosis (F4) had a sixfold higher risk of treatment interruption compared to those with less advanced fibrosis (F2) within the first 24 weeks.
- Hepatitis C virus genotype 3 was associated with a 2.5 times higher risk of treatment cessation after 24 weeks compared to genotype 1.
Conclusions:
- The degree of liver fibrosis and the specific Hepatitis C virus genotype are primary risk factors for treatment interruption.
- These findings highlight the importance of assessing fibrosis stage and genotype for predicting and preventing therapy non-adherence.
Related Concept Videos
01:25Hepatitis
80
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
80
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
01:16Hepatic Drug Excretion: Influencing Factors
806
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
806
01:29Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429